Kidney disease (CKD) is a major healthcare crisis. It is growing at an accelerated rate, rising from 13th to 10th place in the World Health Organization ranking of most common causes of death. It currently represents a huge healthcare economic burden in every country and because of its growth it will be an even larger one in the future unless kidney disease can be detected and treated early.
The Nova Max Pro™ CREAT/eGFR is an important new tool to improve kidney care and treatment through early detection of kidney disease. Creatinine and estimated glomerular filtration rate (eGFR) results are reported (with or without race as a factor) using the CKD-EPI equation from a small, capillary fingerstick blood sample in just 30 seconds.
Results can be sent wirelessly to Bluetooth-enabled apps for provider review. Nova Max Pro technology is based on the Nova StatSensor Creatinine technology which has been used in hospital point-of-care applications for over 15 years.
CE Marked.
Nova Max Pro™ CREAT/eGFR not yet available in the U.S. or Canada.
The ISN AKI Toolkit outlines how to identify patients at risk for AKI. In the absence of creatinine/eGFR baseline value, an elevated serum creatinine/eGFR and appropriate clinical context is highly suggestive.
The StatSensor® and StatSensor Xpress™ Creatinine and eGFR Meters is a handheld analyser and miniaturised, single-use biosensor for whole blood creatinine testing. StatSensor Creatinine's advanced technology enables simple, rapid, and accurate assessment of renal function by fingerstick capillary blood sampling at the point of care. StatSensor results can be automatically transmitted to the Hospital and Laboratory information systems.
CE Marked.
StatSensor Xpress™ not yet available in the U.S. or Canada.
The ISN and KDIGO recently released a series of tools for CKD early identification aimed at kidney health professionals, primary care physicians and nurses. To test high-risk adults, they recommend evaluating kidney function with eGFR and kidney damage with albuminuria.
Allegro® offers blood creatinine and eGFR from a fingerstick capillary blood sample, and urine albumin from a small urine sample on one device. Fast, accurate results make this an ideal device in a clinician or pharmacy setting.
CE Marked.
Allegro® not yet available in the U.S. or Canada.
AKI portends increased ICU stay, increased cost, and compromised outcome. Prime Plus® provides optional whole blood creatinine and BUN (Urea) tests plus eGFR for rapid assessment of kidney function. The BUN/Creatinine ratio also provides an assessment of illness severity, prolonged ICU stay, and prognosis.
pH PCO2 PO2 SO2% Hb Hct Na K Cl TCO2 iCA iMg
Glu Lac Creat eGFR Urea MCHC ePV tBil HbF CO-Ox
CE Marked and FDA-cleared.
HbF and tBil not yet available in all markets, including the US and Canada.